Upcoming

Preview upcoming DAO, IPT and agent launches

Neuron-Gale project image
Neuron-Gale logo

Neuron-Gale

IPT

Galectin-3 Inhibitors project tests a small molecule, previously used in peripheral indications, for treating neuroinflammation in an Alzheimer’s mouse model. By blocking Galectin-3, it aims to reduce brain inflammation, with potential in other neurodegenerative diseases. The Galectin-3 Inhibitors project is testing the concept of treating neuroinflammation through a small molecule known to inhibit Galectin-3 in peripheral indications, via direct injection to the brain in the mouse model of Alzheimer’s disease. Galectin-3 is involved in neuroinflammation, thereby the project has a potential to be used in multiple neurodegenerative diseases. Galectin-3 inhibitors are a new class of drugs that could effectively treat neuroinflammation. Galectin-3 has shown to be a critical element in both peripheral as well as neuroinflammation. The project advances how inhibition leads to a resolution of brain inflammation.

$GALE

Showing 6 of 12 projects

Live

Explore live projects and agents

VitaStem by Aubrai project image
VitaStem by Aubrai logo

VitaStem by Aubrai

IPT

VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.

$VITASTEM

BASE
Showing 6 of 17 projects